|1.||Strupp, Michael: 8 articles (04/2015 - 05/2008)|
|2.||Brandt, Thomas: 7 articles (04/2015 - 05/2008)|
|3.||Lian, Jiamei: 6 articles (10/2015 - 09/2012)|
|4.||Deng, Chao: 6 articles (10/2015 - 09/2012)|
|5.||Strupp, M: 5 articles (12/2015 - 01/2013)|
|6.||Huang, Xu-Feng: 5 articles (01/2015 - 09/2012)|
|7.||Pai, Nagesh: 5 articles (01/2015 - 09/2012)|
|8.||Baumann, Wolfgang: 4 articles (06/2012 - 01/2005)|
|9.||Mira, E: 4 articles (01/2008 - 01/2000)|
|10.||Lacour, Michel: 3 articles (01/2013 - 06/2002)|
|1.||Vertigo (Positional Vertigo)
01/01/2008 - "Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). "
01/01/2005 - "Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores compared with the reference therapy betahistine. "
09/01/2005 - "To evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV). "
01/01/2004 - "Therapeutic efficacy of 2-month betaserc course in peripheral vertigo has been proved."
12/01/2015 - "According to clinical studies, betahistine 48 mg daily during 3 months is an effective and safe option for the treatment of peripheral vertigo."
05/01/2011 - "This study aims to detect whether any differences were present between betahistine dihydrochloride, transcutaneal electrical nerve stimulation and pure tone masking-tinnitus retraining therapy (TRT) methods in the effects on quality of life and treatment of the symptoms of the patients. "
01/01/2001 - "One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. "
07/01/2011 - "The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders."
07/01/2011 - "To assess the effects of betahistine on tinnitus in patients with vestibular disorders. "
07/01/2011 - "Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus. "
|3.||Meniere Disease (Menieres Disease)
01/01/1991 - "From clinical studies, it appears that betahistine is an effective agent for the symptomatic treatment of Meniere's syndrome. "
09/01/1976 - "The management of Meniere's disease with betahistine can be regarded as an improvement in the conservative therapy of this disorder."
01/01/1991 - "Betahistine is the current most effective drug in maintenance therapy of Meniere's disease, although it does not resolve all of the problem of this disorder. "
12/01/1978 - "[Management of Meniere's disease using betahistine]."
09/01/1976 - "Betahistine was gien to 86 patients with Meniere's disease in a thric daily dose of 8 mg. All patients except for three had earlier been treated medically without success. "
|4.||Vestibular Neuronitis (Vestibular Neuritis)
02/01/2013 - "Although progress has been made in the diagnosis and treatment of most peripheral vestibular disorders, more state-of-the-art trials are needed on the treatment of bilateral vestibulopathy to prove the efficacy of balance training, of vestibular neuritis (in terms of recovery of peripheral vestibular function and central compensation), of vestibular paroxysmia to prove the effects of carbamazepine, and of Menière's disease to find the optimal dosage of betahistine."
12/01/2015 - "Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo. "
06/01/2012 - "Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study."
01/01/2008 - "Betahistine was significantly more often prescribed for "unspecified" dizziness, vestibular neuritis, and benign paroxysmal positional vertigo; but not for Meniere's disease. "
07/01/2011 - "Thus, although progress has been made in the treatment of vestibular neuritis, some forms of pathological nystagmus, and EA 2, controlled, masked trials are still needed to evaluate treatments for many vestibular and ocular motor disorders, including betahistine for Ménière's disease, oxcarbazepine for vestibular paroxysmia, or metoprolol for vestibular migraine."
09/01/2012 - "Betahistine treatment alone had no effect on weight gain and food intake. "
10/01/2014 - "Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways."
01/01/2014 - "Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment."
09/01/2012 - "Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model."
03/01/2005 - "Our findings justify a placebo-controlled evaluation of the putative weight-attenuating effect of betahistine in olanzapine-induced weight gain."
|6.||Benign paroxysmal positional vertigo
|7.||Adrenal Cortex Hormones (Corticosteroids)
|8.||Histamine (Histamine Dihydrochloride)
|2.||Drug Therapy (Chemotherapy)
|3.||Low-Level Laser Therapy (LLLT)